公司制剂产品立项评估数据

根据行业专家、一线医生和销售人员的推荐，采集全球范围内医药行业的产品市场信息、注册信息、专利技术信息以及法规信息，结合公司自身技术条件，为企业制剂新产品立项提供多维度情报信息支撑；同时借助大数据分析技术，对相关产品进行全面评估评分，挖掘高价值的目标产品，为制剂产品立项提供精准的线索，提升制剂产品立项工作的效能。第一，数据处理：从各类商业和官方数据库提取产品市场规模、增长趋势、竞争对手、公司生产线和营销能力配合度、专利门槛等提取多个特征值，并根据多个特征值生成该产品的多个技术指标；第二，数据算法：采用机器学习技术中的决策树算法对产品进行评分分级，高分产品作为立项优选。打分列通过如下方式计分：规模8亿以上得1分，8亿以下不得分；增长率10%以上得1分,10%以下不得分；属于公司营销领域得0.5分，不属于不得分；是临床一线得0.5分，不是不得分；原料药公司现有得0.5分，不是不得分；是专利产品不得分，不是得0.5分；制剂产线投资规模低得0.5分，不是不得分。

Based on recommendations from industry experts, frontline clinicians and sales personnel, this dataset collects product market information, registration details, patent technology information and regulatory information from the global pharmaceutical industry, and combines these data with the company's own technical conditions to provide multi-dimensional intelligence support for enterprises' project approval of new formulation products.
Meanwhile, leveraging big data analysis technologies, it conducts comprehensive evaluation and scoring of relevant products, identifies high-value target products, provides precise clues for formulation product project approval, and enhances the efficiency of formulation product project approval work.
First, Data Processing: Extract multiple feature values from various commercial and official databases, including product market size, growth trend, competitors, the matching degree between the company's production lines and marketing capabilities, patent barriers, and generate multiple technical indicators for each product based on these feature values.
Second, Data Algorithm: Adopt the decision tree algorithm from machine learning technologies to perform scoring and grading on products, with high-scoring products serving as preferred candidates for project approval. The scoring criteria are as follows: 1 point for a market size exceeding 800 million, 0 points for below 800 million; 1 point for a growth rate above 10%, 0 points for below 10%; 0.5 points if the product falls within the company's marketing domain, 0 points otherwise; 0.5 points if it is a first-line clinical drug, 0 points otherwise; 0.5 points if the product is manufactured on the company's existing active pharmaceutical ingredient (API) production lines, 0 points otherwise; 0 points if it is a patented product, 0.5 points otherwise; 0.5 points if the investment scale of the formulation production line is low, 0 points otherwise.

搜集汇总

数据集介绍

特点

本数据集提供了浙江仙琚制药股份有限公司的制剂产品立项评估数据，包括市场规模、增长率、竞争对手等关键信息，通过机器学习算法进行评分，旨在为企业制剂新产品立项提供多维度情报支持和精准线索。